Clinical Psychopharmacology and Neuroscience最新文献

{"title":"Identification of Factors to Predict Transition to Schizophrenia in Subjects with Ultra-high Risk for Psychosis: A Protocol for a Multicenter, Longitudinal Study of Sleep Parameters and Cytokine Levels.","authors":"Yuji Yamada, Kazuo Mishima, Takashi Ohnishi, Michio Suzuki, Takahiro Nemoto, Masafumi Mizuno, Toshifumi Kishimoto, Hiroaki Tomita, Motohiro Ozone, Shingo Kitamura, Kenji Hashimoto, Kazuyuki Nakagome, Tomiki Sumiyoshi","doi":"10.9758/cpn.24.1239","DOIUrl":"https://doi.org/10.9758/cpn.24.1239","url":null,"abstract":"<p><strong>Objective: </strong>Schizophrenia is a major psychiatric illness which mostly begins in adolescence and leads to impairments of social functioning. Some patients with schizophrenia have been associated with ultra-high risk state for psychosis (UHR), a condition used to operationally represent the prodromal stage of the illness. In previous studies, the UHR and the progression to overt psychosis has been reported to be accompanied with alterations in the quality of sleep and the immune system, as represented by change of blood levels of cytokines. Currently, biomarkers to predict the development of psychosis in persons at UHR have not yet reached a steady consensus. Therefore, we present a study protocol to explore predictors of transitions to psychosis, in the realm of monitoring of sleep condition and cytokine measurement, in subjects with the UHR.</p><p><strong>Methods: </strong>This is a multicenter, longitudinal cohort study participated by 7 hospitals in Japan. We will recruit 50 UHR people and 30 healthy volunteers as a control group, and measure positive symptom, depressive symptoms, cognitive function, and social function. Blood cytokines levels and sleep indices, as well as actigraphy data will be monitored. After the baseline assessment, clinical symptoms, sleep indices, and cytokine levels will be measured every 12 weeks for 52 weeks. Actigraphy devices will continue to be worn for 52 weeks, while social function will be assessed over 104 weeks. The results of this study are expected to facilitate the development of novel intervention therapies to reduce the risk of psychosis and improve functional outcomes.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"266-277"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Cholinesterase Inhibitors on Neurodegeneration in Individuals with Amnestic Mild Cognitive Impairment.","authors":"Gihwan Byeon, Min Soo Byun, Dahyun Yi, Hyejin Ahn, Gijung Jung, Bo Kyung Sohn, Joon Hyung Jung, Yoon Young Chang, Kyungtae Kim, Hyeji Choi, Yoon Hee Kim, Yu Kyeong Kim, Koung Mi Kang, Chul-Ho Sohn, Dong Young Lee","doi":"10.9758/cpn.24.1238","DOIUrl":"https://doi.org/10.9758/cpn.24.1238","url":null,"abstract":"<p><strong>Objective: </strong>Cholinesterase inhibitors (ChEIs) are effective in treating mild to moderate Alzheimer's disease (AD) dementia by compensating for acetylcholine deficiency. While their use in mild cognitive impairment (MCI) lacks strong trial support, some studies suggest they may delay neurodegeneration. This study aims to investigate ChEIs' neuroprotective effects in individuals with amnestic MCI (aMCI) using multi-modal neuroimaging, and to determine if amyloid-beta (Aβ) deposition influences these effects.</p><p><strong>Methods: </strong>Longitudinal data from a cohort study were retrospectively analyzed. A total of 118 aMCI patients (ages 55- 90), who underwent baseline evaluations encompassing the assessment of ChEI use and [¹¹C] Pittsburgh compound B-positron emission tomography (PET), were included in the analyses. All participants also received baseline and 2-year follow-up magnetic resonance imaging and [¹⁸F] fluorodeoxyglucose-PET imaging.</p><p><strong>Results: </strong>The ChEI use group exhibited a significantly lesser decline in AD-signature region cerebral metabolism (AD-CM) over a 2-year period than the ChEI non-use group (B = 0.089, 95% CI: 0.030-0.149). However, there was no significant difference in the 2-year change of AD-signature region cortical thickness (AD-CT) (B = 0.032, 95% CI: -0.075 to 0.138) and hippocampal volume (B = -88.013, 95% CI: -323.900 to 147.874) between the ChEI use and non-use groups. The presence of Aβ pathology did not moderate the effect of ChEI use on AD-CM, AD-CT, or hippocampal volume.</p><p><strong>Conclusion: </strong>The findings suggest that ChEIs may delay functional neurodegeneration in aMCI individuals, irrespective of the presence of amyloid pathology.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"256-265"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interplay of Physical Activity, Muscle Strength, and Depression in Cognitive Impairment among Korean Older Adults: A Cross-sectional Study.","authors":"Youngyun Jin, Taewan Kim, Jinkyung Cho","doi":"10.9758/cpn.24.1237","DOIUrl":"https://doi.org/10.9758/cpn.24.1237","url":null,"abstract":"<p><strong>Objective: </strong>The present study was to investigate the association of physical activity (PA), relative-handgrip strength (RHGS), depressive symptoms, and cognitive impairment in Korean older adults.</p><p><strong>Methods: </strong>This study included 512 community-dwelling Korean older adults (417 female, 95 male) aged ≥ 65 years (74.8 ± 5.4 years). PA and RHGS were assessed using an accelerometer and dynamometer, respectively. Depressive symptoms were evaluated by the Korean form of the Center for Epidemiologic Studies Depression (CES-D) Scale. Cognitive impairment was assessed through the Mini-Mental State Examination for Dementia Screening (MMSE-DS).</p><p><strong>Results: </strong>Multiple logistic regression analysis revealed that depressive symptoms (odds ratio [OR] = 2.676, 95% confidence interval [CI]: 1.594-4.492, <i>p</i> < 0.001) showed a significant association with increased odds of cognitive impairment compared with normal depression status (OR = 1). Depressive symptoms had both direct and indirect effects on cognitive impairment. Both PA and RHGS partially mediated the relationship between depressive symptoms and cognitive impairment (PA: effect [B] = -0.017, 95% CI: -0.028 to -0.009, <i>p</i> < 0.001; RHGS: B = -0.005, 95% CI: -0.007 to -0.003, <i>p</i> < 0.001). Serial mediation analysis further indicated that the association between depressive symptoms and cognitive impairment was sequentially mediated by PA and RHGS (B = -0.004, 95% CI: -0.006 to -0.002, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Promoting PA among older adults may be crucial, as this helps improve and maintain muscular strength and mitigates the negative impact of depressive symptoms on cognitive impairment.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"246-255"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Cognitive Impairment and Peripheral Inflammation in Methamphetamine-dependent Patients: A Cross-sectional Study on Neuroinflammatory Markers TNF-α and IL-6.","authors":"Kannika Permpoonputtana, Jatuporn Namyen, Doungjai Buntup, Parichart Boontem, Chutikorn Nopparat, Piyarat Govitrapong","doi":"10.9758/cpn.24.1236","DOIUrl":"https://doi.org/10.9758/cpn.24.1236","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the cognitive impairment and peripheral inflammation induced by methamphetamine (METH) and their association in METH abusers.</p><p><strong>Methods: </strong>The cross-sectional study included 100 METH-dependent patients and 100 healthy controls. Cognitive screening was conducted using the Thai version of the Montreal Cognitive Assessment (MoCA-T). Thirty normal controls and 30 METH-dependent patients were randomly selected for blood collection to measure inflammatory markers, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, using a quantitative enzyme-linked immunosorbent assay method.</p><p><strong>Results: </strong>METH-dependent patients had significantly poorer MoCA-T scores and higher levels of blood inflammatory markers compared to healthy controls. Demographic characteristics, METH use patterns, and proinflammatory cytokines were associated with cognitive impairment. The MoCA-T score was negatively associated with plasma TNF-α and IL-6 levels.</p><p><strong>Conclusion: </strong>METH-associated cognitive decline is correlated with elevated plasma levels of TNF-α and IL-6 cytokines, indicating the involvement of specific neuroinflammatory pathways in neurocognitive dysfunction. These insights could pave the way for novel therapeutic strategies aimed at mitigating neuroinflammation, potentially improving outcomes for individuals with METH addiction.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"234-245"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association between Childhood Trauma on Executive Functioning and Treatment Outcomes among Individuals with Methamphetamine Use Disorder.","authors":"Cheng-Tsung Lin, Tzu-Yun Wang, Tsung-Yu Tsai, Huai-Hsuan Tseng, Kao Chin Chen, I Hui Lee, Po See Chen, Yen Kuang Yang, Ru-Band Lu","doi":"10.9758/cpn.24.1248","DOIUrl":"https://doi.org/10.9758/cpn.24.1248","url":null,"abstract":"<p><strong>Objective: </strong>Childhood trauma is associated with executive function impairment and an increased risk of methamphetamine (MA) use. MA use itself also compromises executive function. Limited evidence is known about the association between childhood trauma, executive functioning and treatment outcomes among individuals with MA use disorder (MAUD). The study explored whether patients with MAUD who had experienced childhood trauma presented poorer executive function and treatment outcomes.</p><p><strong>Methods: </strong>The participants were individuals with MAUD and were all recruited from an outpatient-based addiction clinic from 2019 to 2022. Childhood trauma was assessed using Childhood Trauma Questionnaire-Short Form. The Wisconsin Card Sorting Test (WCST), Severity of Dependence Scale (SDS), and Visual Analog Scale for Craving, and urine MA/amphetamine tests were assessed repeatedly during the one-year treatment program. Generalized estimating equations were used to estimate the changes in these outcomes.</p><p><strong>Results: </strong>In 115 MAUD patients we recruited those with a history of childhood physical neglect (PN) exhibited inferior WCST performance on number of categories completed (<i>p</i> = 0.02), and conceptual level responses (<i>p</i> = 0.046) and were more likely to test positive for MA/amphetamine in urine during the one-year treatment (<i>p</i> = 0.02). Patients with PN also reported significantly more severe cravings (<i>p</i> = 0.002), while those with a history of sexual abuse (SA) had notably higher SDS scores (<i>p</i> = 0.004) during treatment.</p><p><strong>Conclusion: </strong>Childhood trauma, particularly PN and SA, shows substantial adverse effects on executive function and treatment outcomes among MAUD patients.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"300-311"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tics Induced by Mirtazapine in an Adolescent.","authors":"Senem Yapar, Nurullah Bolat","doi":"10.9758/cpn.24.1211","DOIUrl":"https://doi.org/10.9758/cpn.24.1211","url":null,"abstract":"<p><p>Mirtazapine is an antidepressant approved by the FDA whose mechanism of action involves antagonism of alpha-2, H1, 5-HT2A, 5-HT2C, and 5-HT3 receptors. Tics are sudden, rapid, purposeless, recurrent, non-rhythmic motor movements or vocalizations. There have been previous case reports of various medications causing tics. In this article, we report tic symptoms that we thought developed in association with mirtazapine treatment.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"319-322"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positive Airway Pressure Treatment Effects on the Serum Nod-like Receptor Protein 3 and Nitric Oxide Levels in Obstructive Sleep Apnea Syndrome.","authors":"Emine Kılıçparlar Cengiz, Yasemin Ekmekyapar Fırat, Meltem Güngör, İhsan Berk, Abdurrahman Neyal, Eyüp İlker Saygılı, Ayşe Münife Neyal","doi":"10.9758/cpn.24.1235","DOIUrl":"https://doi.org/10.9758/cpn.24.1235","url":null,"abstract":"<p><strong>Objective: </strong>Obstructive sleep apnea syndrome (OSAS) is associated with recurrent apnea episodes. Positive airway pressure (PAP) treatment prevents repeatedly hypoxia in OSAS. Serum nitric oxide (NO) and Nod-like receptor protein 3 (NLRP3), that are involved in inflammation and pyroptotic cell death, may be affected hypoxia in OSAS. If so preventing hypoxia-ischemia episodes by PAP treatment may change serum NLRP3 and NO levels in OSAS. We aimed to determine whether serum levels of NLRP3 and NO change after at least 3 months of treatment with PAP.</p><p><strong>Methods: </strong>Twenty-five OSAS patients, including 17 men and 8 women, who underwent polysomnography (PSG) and had an apnea-hypopnea index (AHI) of 30 or more and had started treatment at PAP. AHI was recorded. Serum levels NO and NLRP3 were analyzed before and at least 3 months after PAP treatment.</p><p><strong>Results: </strong>After treatment with the PAP device, serum NO levels were significantly increased, NLRP3 levels were significantly decreased compared to pre-treatment levels (<i>p</i> < 0.001, <i>p</i> = 0.003). No correlation was found between serum NLRP3 and NO levels, AHI, type of the PAP device before or after PAP treatment.</p><p><strong>Conclusion: </strong>We revealed that PAP treatment which prevents hypoxia, can alter the serum levels of NO and NLRP3 in OSAS, that is not related to the severity of AHI or type of the PAP device. This is the first study to measure NLRP3 levels before and after treatment with PAP in OSAS patients. Prospective studies with large cohorts and longitudinal follow-up evaluation of complications may provide further insights.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"227-233"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interplay between Stressful Life Events and Interleukin-1β on 12-week Antidepressant Response in Depressive Patients.","authors":"Ye-Jin Kim, Ju-Wan Kim, Hee-Ju Kang, Ju-Yeon Lee, Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim","doi":"10.9758/cpn.24.1222","DOIUrl":"https://doi.org/10.9758/cpn.24.1222","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the moderating effects of interleukin-1β (IL-1β) on the relationship between stressful life events (SLEs) and antidepressant treatment outcomes over 12 weeks in patients with depressive disorders.</p><p><strong>Methods: </strong>Baseline assessments of SLEs, IL-1β levels, and other covariates were conducted for 1,094 depressive outpatients with 1,086 followed up for 12 weeks. Antidepressant treatment was tailored according to clinician recommendations and patient preferences, with outcomes evaluated at 12 weeks using the Hamilton depression rating scale. Logistic regression analyses explored the individual and interactive effects of SLEs and IL-1β on depression remission.</p><p><strong>Results: </strong>SLEs alone did not predict 12-week remission (OR = 0.93, 95% CI [0.82, 1.06]). However, IL-1β levels significantly influenced outcomes (OR = 0.67, 95% CI [0.53, 0.87]), particularly in conjunction with high SLE exposure (Wald = 13.29, <i>p</i> < 0.001). Higher IL-1β levels were associated with lower odds of achieving remission in the group with two or more SLEs (OR = 0.46, 95% CI [0.33, 0.65]), whereas in the group with fewer than two SLEs, the odds were not significantly different (OR = 1.13, 95% CI [0.77, 1.65]).</p><p><strong>Conclusion: </strong>These findings highlight the critical role of both biological markers and environmental stressors in antidepressant treatment. IL-1β could serve as a biomarker for customizing antidepressant strategies, particularly in patients experiencing high SLE exposure, thereby enhancing treatment efficacy and personalized care. Future studies should include longitudinal assessments of IL-1β to further elucidate its dynamic role in depression pathology and treatment response.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"184-192"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Erythropoietin and Erythropoietin Receptor Levels in Children with Autistic Spectrum Disorder: Cross-sectional Study.","authors":"Erkan Oner, Ergul Belge Kurutas, Hatice Altun","doi":"10.9758/cpn.24.1230","DOIUrl":"https://doi.org/10.9758/cpn.24.1230","url":null,"abstract":"<p><strong>Objective: </strong>Autistic spectrum disorders (ASD) are a heterogeneous collection of neurodevelopmental disorders with an unknown etiology. Erythropoietin is a versatile growth factor that plays a crucial role in the nervous system, exhibiting high expression in various regions of the brain, including neurons, glial cells and endothelial cells. Recent animal studies have demonstrated that Epo exerts neuroprotective and neurotrophic effects. The objective of this study was to examine the levels of erythropoietin-(Epo) and its receptor-(EpoR) in children with ASD and to elucidate the potential effects of Epo in the disorder.</p><p><strong>Methods: </strong>The study involved 50 children diagnosed with ASD based on the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders criteria, with ASD severity assessed using the Childhood Autism Rating Scale. Additionally, a control group of 50 healthy children was included. Serum samples were collected from both groups, and levels of Epo and its EpoR.</p><p><strong>Results: </strong>There were no statistically significant differences between the age and sex distributions of the ASD and control groups (<i>p</i> > 0.05). However, analysis of the serum samples revealed a statistically significant reduction in Epo levels in the ASD cohort compared to the control.</p><p><strong>Conclusion: </strong>The results of our study indicate that Epo may have potential as an adjunctive therapy for children with ASD. The observed decrease in Epo levels and increase in EpoR levels in children with ASD suggest a dysregulation in the Epo-EpoR axis that may contribute to the pathophysiology of ASD. Further research is required to investigate the therapeutic effects of modulating Epo levels in ASD and to elucidate the mechanisms underlying these changes.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"212-218"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>miR-26b</i>, <i>miR-30e</i>, and <i>miR-206</i> Polymorphisms May Play a Role in <i>BDNF</i>-mediated Development of Alzheimer's-type Dementia.","authors":"Ayten Tuna, Olcay Boyacioglu, Ayse Dondu, Seda Orenay-Boyacioglu","doi":"10.9758/cpn.24.1223","DOIUrl":"https://doi.org/10.9758/cpn.24.1223","url":null,"abstract":"<p><strong>Objective: </strong>The brain-derived neurotrophic factor (BDNF) playing a crucial role in neuron survival and function, particularly in neurodegenerative diseases like Alzheimer's disease (AD). Our study seeks to explore polymorphisms in miRNAs that regulate the <i>BDNF</i> gene in individuals with AD, and to reveal the relationship between these polymorphisms and <i>APOE</i> genotypes.</p><p><strong>Methods: </strong>Seventy AD patients who applied to the Psychiatry outpatient clinic were recruited for the study as well as 70 healthy individuals in the same age. The cases were examined for 5 miRNAs regulating <i>BDNF</i> and 2 <i>APOE</i> SNPs using the SNPType method on the Fluidigm platform.</p><p><strong>Results: </strong>In comparisons of the genotype distributions for three polymorphisms (<i>miR-206 rs16882131</i>, <i>miR-30e rs112439044</i>, <i>miR-26b rs188612260</i>) (<i>p</i> < 0.01 all) and the allele frequencies for two polymorphisms (<i>miR-30e rs112439044</i>, <i>miR-26b rs188612260</i>) (<i>p</i> < 0.01) detected significant differences between groups. While the <i>APOE</i> <i>e4/e4</i> genotype was detected in 4.50% of the AD group, no individual with this genotype was observed in the control group. When the correlation between miRNA polymorphisms and <i>APOE</i> genotypic distributions were investigated, the <i>miR-30e rs10489167</i> polymorphism showed a statistically significant positive correlation with the <i>ε2/ε2</i> genotype and a statistically significant negative correlation with the <i>e2/e3</i> genotype (<i>p</i> < 0.08 and <i>p</i> < 0.001, respectively). On the other hand, the <i>miR-30e rs112439044</i> polymorphism exhibited a statistically significant positive correlation with the <i>e2/e2</i> and <i>ε2/ε2</i> genotypes (<i>p</i> < 0.03 and <i>p</i> < 0.07, respectively).</p><p><strong>Conclusion: </strong>These findings could potentially offer insights into the mechanisms underlying AD.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"23 2","pages":"193-201"},"PeriodicalIF":2.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}